RT Journal Article
T1 Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review.
A1 Grande, Enrique
A1 Díaz, Ángel
A1 López, Carlos
A1 Munarriz, Javier
A1 Reina, Juan-José
A1 Vera, Ruth
A1 Bernárdez, Beatriz
A1 Aller, Javier
A1 Capdevila, Jaume
A1 Garcia-Carbonero, Rocio
A1 Jimenez Fonseca, Paula
A1 Trapero-Bertran, Marta
K1 budget impact
K1 cost-of-illness
K1 costs
K1 economic burden
K1 economic evaluation
K1 gastroenteropancreatic neuroendocrine tumors
K1 resource utilization
K1 systematic review
AB Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. Compounding the issue is that data on resource utilization and cost-effectiveness of different diagnostic and therapeutic modalities for GEP-NETs are scarce. A systematic review on the economic impact of GEP-NETs was carried out using four databases: EMBASE, PubMed, the National Health Service Economic Evaluation Database and Cochrane review. Fully published articles from January 2000 to May 2017, in English and Spanish, were included. All articles that satisfied the inclusion criteria were included in the systematic review; summary descriptive statistics were used to describe the methodological characteristics. The 14 studies selected included cost-of-illness analyses (n = 4), economic evaluations (n = 7) and budget impact analyses (n = 3). Almost all studies were performed in the United States. Healthcare costs for patients with NETs included medication, outpatient visits, hospitalizations, and check-ups/tests. Reducing adverse events is an area where cost savings could be achieved; however, there was not enough evidence on the cost impact of adverse events. There is a lack of data related to resource utilization in the field of GEP-NETs. Therefore, cost-effectiveness and budget impact studies of existing and emerging treatments are urgently needed to help the decision-making process for patients with NETs.
SN 2042-0188
YR 2019
FD 2019-02-18
LK http://hdl.handle.net/10668/13639
UL http://hdl.handle.net/10668/13639
LA en
DS RISalud
RD Apr 7, 2025